p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Siyu DengMengna WangChenglong WangYan ZengXue QinYiwen TanBing LiangYoude CaoPublished in: Molecular biology reports (2022)
Our research may provide a novel potential target for TNBC.